**To the Editor:** Colistin is a last-line drug for treatment of multidrug-resistant, gram-negative bacterial infections, including those caused by *Escherichia coli*. We report colistin-resistant *E. coli* isolates from Japan, including a global-spreading pathogenic lineage, serotype O25b:H4, sequence type (ST) 131, and subclone *H*30-R (O25b:H4-ST131-*H*30R).

We tested 514 *E. coli* isolates obtained from clinical specimens taken at Sapporo Clinical Laboratory Inc. (Sapporo, Japan) and Sapporo Medical University Hospital in Japan during 2008--2009 ([@R1]) and 2015, respectively. Samples were processed according to Clinical and Laboratory Standards Institute guidelines ([@R2]). Identification of O25b:H4-ST131, O25b, H4, and ST131 were determined as described previously ([@R1]). For identification of the *H*30Rx subclone of O25b:H4-ST131, *H*30 was determined by PCR using a specific primer set ([@R3]), R was determined according to ciprofloxacin MIC, and x was determined by detecting 2 single-nucleotide polymorphisms, as previously described ([@R4]).

Four *E. coli* isolates exceeded the colistin resistance breakpoint (\>2 mg/mL) ([Table](#T1){ref-type="table"}). None of the patients from whom the *E. coli* isolates were derived had a history of colistin treatment. Three of the 4 colistin-resistant isolates belonged to a pandemic lineage, O25b:H4-ST131-*H*30R, which has been isolated from urinary tract and bloodstream infections ([@R3],[@R4]). The frequency of colistin-resistant ST131 *E. coli* isolates among O25b:H4-ST131 was 2.2%. This lineage is fluoroquinolone resistant and is frequently resistant to β-lactams because it possesses CTX-M--type extended-spectrum β-lactamase genes ([@R1],[@R3],[@R4]).

###### Characterization of colistin-resistant *Escherichia coli* isolates, Japan, 2008--2105\*

  Strain   Specimen type                  Patient age, y/sex   Year   Serotype   ST           MIC, mg/L†                                                                                                  
  -------- ------------------------------ -------------------- ------ ---------- ------------ ------------ --------- ----------- ------------ ----------- --------- -------- ---------- ----------------- ---------
  SRE34    Urine catheter                 UNK/F                2008   O25b:H4    131- H30Rx   128 (R)      1  (S)    1  (S)      0.06 (S)     0.125 (S)   0.5 (S)   2  (S)   32 (R)     16 (R), 16 (R)‡   8,  8‡
  SRE44    Urine catheter                 UNK/M                2008   O25b:H4    131- H30Rx   64 (R)       2  (S)    1  (S)      0.13  (S)    0.25 (S)    0.5 (S)   1  (S)   64 (R)     16 (R), 16 (R)‡   16,  8‡
  SME222   Indwelling pericardial drain   76/M                 2015   O18        416          2  (S)       0.5 (S)   0.5 (S)     \<0.03 (S)   0.13 (S)    0.5 (S)   2  (S)   0.03 (S)   4 (R),  4 (R)‡    8,  4‡
  SME296   Urine                          67/M                 2015   O25b:H4    131- H30R    \>128 (R)    32 (R)    \>128 (R)   16 (R)       0.13 (S)    0.5 (S)   2  (S)   64 (R)     4 (R),  8 (R)‡    1,  4‡

\*All isolates were phylogentic group B2. AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CPD, cefpodoxime; FEP, cefepime; CST, colistin; GEN, gentamicin; IPM, imipenem; PIP, piperacillin; PMB, polymyxin B; R, resistant; S, susceptible; ST, sequence type; UNK, unknown. †EUCAST (<http://www.eucast.org/>) breakpoints were used for resistance determination because the colistin breakpoint for *E. coli* was undetermined by the Clinical and Laboratory Standards Institute. MICs were determined by the agar dilution method unless otherwise stated. Breakpoints: PIP, \>16; CAZ, \>16; CPD, \>1; FEP, \>4; IPM, \>8; GEN, \>4; AMK, \>16; CIP, \>1; CST, \>2. ‡Broth microdilution method.

The colistin-resistant isolates reported were resistant to fluoroquinolones, and 1 (SME296) was resistant to cephalosporins (due to expression of *bla*~CTX-M-14~). Another colistin-resistant *E. coli* isolate (SME222) belonged to O18-ST416, which is also known as an extraintestinal pathogenic *E. coli* ([@R5]), although this lineage has not previously been reported to exhibit colistin resistance.

The colistin-resistant *E. coli* isolates we identified were sensitive to carbapenems and aminoglycosides, including amikacin, whereas previously it was reported that some *E. coli* ST131 isolates exhibited resistance to carbapenems by possessing carbapenemases, such as NDM-1 and KPC-2; the NDM-1--possessing ST131 isolate also exhibited resistance to amikacin ([@R6],[@R7]). Thus, these findings may affect future antimicrobial choices because of the clonal dominance, multidrug resistance, and pathogenicity of the isolates.

Recent studies reported a plasmid-mediated colistin resistance gene, *mcr-1*, in various countries ([@R8]). In addition, a novel plasmid-mediated colistin resistance gene, *mcr-2* (76.7% nucleotide identity to *mcr-1*), was found in *E. coli* isolates in Belgium ([@R9]). These genes encode a phosphoethanolamine transferase family protein, which modifies the lipid A component of lipopolysaccharide ([@R8],[@R9]). The colistin-resistant *E. coli* isolates we identified did not possess *mcr-1*or *mcr-2*, although the MICs for colistin were the same as or higher than that of the transconjugant of a *mcr-1*--harboring plasmid in an *E. coli* ST131 isolate (4 mg/L) reported by Liu et al. ([@R8]). Thus, these colistin-resistant isolates may have other colistin resistance mechanisms. For example, modification of lipid A with 4-amino-4-deoxy-[l]{.smallcaps}-arabinose or phosphoethanolamine, caused by chromosomal mutations in *mgrB*, *phoPQ*, and *pmrAB* genes, might occur and could be responsible for the resistance. This polymyxin-resistance mechanism is seen in *Enterobacteriaceae*; however, other novel mechanisms are also conceivable.

In conclusion, we report colistin resistance in a major global-spreading extraintestinal pathogenic *E. coli* strain, O25b:H4-ST131-*H*30R, in Japan. This strain acquired colistin resistance without carrying a plasmid bearing the *mcr* gene. Clarifying the colistin-resistance mechanisms in these isolates is necessary if we are to forestall the emergence of multidrug (including colistin)--resistant O25b:H4-ST131-*H*30R. The worst-case scenario is the global spread of this isolate, which has acquired resistance to the last-line antimicrobial drug, colistin.
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